The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1275 articles
GLP-1 weight loss drugs like Ozempic may trim airline fuel bills alongside waistlines. A Jefferies report estimates $580M annual savings for top US carriers from lighter passengers. Discover the science and implications.
Popular GLP-1 drugs are delivering unexpected savings to airlines, with $580 million in annual fuel cost reductions projected for major U.S. carriers. Analyst Sheila Kahyaoglu's research links passenger weight loss to lower operating expenses. Discover how this weight management trend reshapes aviation economics.
Doctor Karan Rajan explains why you might regain weight after quitting GLP-1 drugs: they mimic treatments for chronic conditions like high blood pressure. Obesity requires ongoing management with lifestyle factors like diet, exercise, and sleep. Not everyone needs GLP-1s forever, but stopping without changes risks relapse.
Novo Nordisk introduces the 'There's Only One Ozempic' campaign, reuniting comedy duo Justin Long and John Hodgman to spotlight Ozempic's unique FDA-approved benefits for type 2 diabetes. The effort uses humor and education to distinguish genuine Ozempic (semaglutide) from unapproved compounded versions. It encourages vital conversations between patients and healthcare providers.
One-third of South Africans live with obesity, driving new clinical guidelines that endorse GLP-1 drugs like Ozempic, Mounjaro, and Wegovy. These medications lower blood sugar, slow digestion, and promote fullness but face affordability barriers. Experts urge political action for broader access.
Daily tasks like banking and food delivery are fully digital, yet healthcare remains outdated. In Nigeria, 47.7% of educated adults self-medicate antibiotics, driving antimicrobial resistance deaths. Digital platforms and GLP-1 weight loss programs offer seamless, compliant solutions.
Semaglutide-based Ozempic has become a weight loss sensation beyond diabetes treatment. Yet, over 1,800 US lawsuits signal serious risks including gastroparesis, bowel issues, and vision loss from NAION. UK and Irish prescribers face growing negligence exposure.
GLP-1 receptor agonists drive effective weight loss but can accelerate bone and muscle loss in postmenopausal women. Aging naturally reduces muscle mass and bone density, and rapid weight loss amplifies these risks. Protect your health with resistance exercise, adequate protein, and comprehensive monitoring.
GLP-1 drugs mimic natural hormones to reduce hunger, slow digestion, and control blood sugar, aiding weight loss and type 2 diabetes. In Malaysia, over 54% of adults are overweight or obese, prompting Health Ministry rollout for vulnerable groups in 2026. Understand benefits, risks, and safe use guidelines.
